

CV

Assoc. Prof. Snežana Mugoša, MD, PhD, Specialist in Internal Medicine



Managing Director of the Institute for Medicines and Medical Devices

Associate Professor at the Faculty of Medicine in Podgorica

Personal Information

Date of birth: 14 February 1979

Place of birth: Nikšić, Montenegro

Email: snezana.mugosa@cinmed.me

Professional Experience

Institute for Medicines and Medical Devices – CInMED

Managing Director 2022 –

Deputy Managing Director 2021 – 2022.

Head of the Department for Clinical Trials and Medicines Safety and Efficacy Assessment 2012 – 2022.

Clinical Research Academy (CRA), Belgrade

Lecturer 2013 –

Faculty of Medicine of the University of Montenegro

Associate Professor in Clinical pharmacy and Pharmacotherapy

Pharmacology group of medical subjects 2021 –

Teaching Associate, Pharmacology group of medical subjects 2004 – 2021.

Centre for Cardiology, Clinical Centre of Montenegro

Specialist in internal medicine 2011 – 2012.

Resident in internal medicine 2006 – 2011.

Podgorica Health Centre, Emergency Medical Care Centre

Physician 2004 – 2005.

Education

Subspecialisation in Clinical Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Belgrade – one-year programme. Qualified as a Subspecialist in Clinical Pharmacology and Pharmacotherapy in 2025, having passed the final examination with a grade of A.

Doctoral Studies, Faculty of Medicine, University of Montenegro, Podgorica – three-year programme. Doctoral dissertation in the field of clinical pharmacology and therapeutics, entitled “*Analysis of Risk Factors for Adverse Medicine Reactions in Cardiac Patients*”, defended in 2015 with a grade of A.

Specialisation in Internal Medicine, Faculty of Medicine, University of Belgrade – four-year programme. Qualified as a Specialist in Internal Medicine in 2011, having passed the specialist examination with the grade Excellent (5).

Master’s Studies in Clinical Pharmacology and therapeutics, Faculty of Medicine, University of Belgrade – two-year programme. Master’s thesis entitled “Intensive Monitoring of Adverse Medicine Reactions in Hospitalised Patients in a Cardiology Department: A Pilot Project”, defended in 2009 with a grade of A.

Faculty of Medicine, University of Montenegro, Podgorica – graduated in 2004 with an average grade of 9.69, the highest in her graduating class.

“Stojan Cerović” Grammar School, Nikšić – named Student of the Generation.

“Olga Golović” Primary School, Nikšić – named Student of the Generation.

Professional qualifications and certificates

Extensive experience in expert and managerial roles in the field of medicines and medical devices regulation.

Expert and scientific research training in the fields of clinical pharmacology, pharmacotherapy, pharmacovigilance, pharmacoepidemiology, pharmacogenetics, clinical trials and consumption of medicines.

European Medicines Agency certificate as a Good Clinical Practice (GCP) inspector.

Training in conducting experiments on experimental animals, Faculty of Medicine, University of Belgrade.

Passed the professional examination for employment in state authorities.

International Projects

Project Lead of Erasmus+ project Development and Implementation of Metacognitive Problem-Based Modules in Blended Learning Courses in Medical Sciences (ProBLEMS), within the programme Capacity Building in Higher Education (CBHE) (2023–2026).

Researcher in the international project COST Action CA24165 – Network for Cardiovascular Pharmacogenomics and Precision Medicine (CardioPharmaGENET) (2025–2029).

Management Board Member of the international project COST Action CA23154 – Environmental Impact of Anthelmintics in Livestock and Alternatives to Minimize Their Use (ENVIRANT) (2024–2028).

Management Board Member and a Researcher in the international project COST Action CA18217 – European Network for Optimization of Veterinary Antimicrobial Treatment (ENOVAT) (2019–2023).

Project Leader of the EU Twinning Project with the Croatian Agency for Medicinal Products and Medical Devices (HALMED), entitled “Support to the Institute for Medicines and Medical Devices of Montenegro” (2021–2022).

National Projects

Participant in a national scientific research project NANOTIN – New Triphenyltin(IV) Complexes with Mixed Ligands Incorporated into Mesoporous Silica Nanoparticles: Synthesis, Characterization and Evaluation of Biological Activity and Antitumour Potential, Ministry of Education, Science and Innovations of Montenegro /CInMED (2026–2028).

Researcher in the national scientific research project “Analysis of Risk Factors for Adverse Medicine Reactions in Cardiac Patients”, led by the Agency for Medicines and Medical Devices of Montenegro (2013–2015).

Membership in Professional and International Associations

Member of the Medical Chamber of Montenegro.

Member of the European Association for Clinical Pharmacology and Therapeutics (EACPT).

Member of the Association of Clinical Research Professionals (ACRP).

Member of the Association for the Advancement of Clinical Trials of Serbia (KLINIS).

Member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Member of the International Society of Pharmacovigilance (ISoP).

Member of the Montenegrin Society for the Fight Against Cancer.

Member of the Animal Protection Association of Montenegro.

Foreign languages and digital skills

English – advanced level (C1)

Advanced digital skills, including ECDL (*European Computer Driving Licence*) certificate.

Full-Text Scientific Research Publications

1. Pantić IV, **Mugoša S**. Artificial intelligence strategies based on random forests for detection of AI-generated content in public health. *Public Health*. 2025;242:382–7.
doi:10.1016/j.puhe.2025.03.030.
2. Vojinović A, Medarević Đ, Stanojević G, Mirković D, **Mugoša S**, Adamov I, et al. Development and evaluation of 3D-printed losartan potassium tablets using semi-solid extrusion: the effect of geometry, drug loading and superdisintegrant. *Pharmaceuticals (Basel)*. 2025;18(10):1504.
doi:10.3390/ph18101504.
3. Kovačević Z, Tomanić D, Šarić L, **Mugoša S**, Budinski K, Novaković D, et al. Exploring pet owners' attitudes toward compounded and human approved medicines: a questionnaire based pilot study. *Vet Res Commun*. 2025;49(2):64.
doi:10.1007/s11259-024-10635-2.
4. **Mugoša S**, Tomanić D, Ibrić S, Boljević G, Kovačević Z. Exploring the potential of integrating 3D printing in veterinary medicine to address antimicrobial resistance: a review. *Farmacia*. 2025;73(3):525–534.
doi:10.31925/farmacia.2025.3.1.
5. Vukićević V, **Mugoša S**, Stanojević G, Vezmar Kovačević S. How effective is the implementation of the valproate pregnancy prevention programme in Montenegro? A 7-year national retrospective study. *Ther Adv Drug Saf*. 2025;16:20420986251360888.
doi:10.1177/20420986251360888.
6. **Mugoša S**, Krivokapić M, Tomanić D, Šarić L, Kovačević Z. A decade of antibacterial drug consumption for systemic use in Montenegro (2014–2023): trends, patterns, and AWaRe classification insights. *Vojnosanit Pregl*. 2025;82(10):653–661.
doi:10.2298/VSP250424068M
7. **Mugoša S**, Meštrović A, Vukićević V, Žugić M, Rouse MJ. SMART Pharmacist—the impact of education on improving pharmacists' participation in monitoring the safety of medicine use in Montenegro. *Pharmacy (Basel)*. 2025;13(2):57.
doi:10.3390/pharmacy13020057.
8. Rašković A, Steinbach M, **Mugoša S**, Baljak J, Prodanović D, Sabo S, et al. Patient information leaflets: how do patients comprehend and understand drug information? *Arch Pharm Pract*. 2024;15(1):7–11.
doi:10.51847/n2jlaSAlbK.
9. Bukumirić Z, Stanisavljević D, Milić N, Ćirković A, Milin-Lazović J, **Mugoša S**, et al. Assessing psychometric properties of the Serbian version of the Metacognitive Awareness Inventory (MAI). *Srp Med Cas Lek Komore*. 2024;5(4):543–554.
doi:10.5937/smcl5-55246.
10. Kovačević Z, Mihajlović J, **Mugoša S**, Horvat O, Tomanić D, Kladar N, et al. Pharmacoeconomic analysis of the different therapeutic approaches in control of bovine mastitis: phytotherapy and antimicrobial treatment. *Antibiotics (Basel)*. 2023;12(1):11.
doi: 10.3390/antibiotics12010011
11. **Mugoša S**, Vračar V, Tešin N, Mitrović J, Tomanić D, Kovačević Z. Antimicrobial veterinary drug sale pattern in correlation with critically important antimicrobials for human use: a five-year study in Montenegro. *Acta Microbiol Immunol Hung*. 2023;70(4):340–347.
doi:10.1556/030.2023.02116.
12. Kovačević Z, **Mugoša S**, Lalić-Popović M, Stojanović S, Tešin N, Marić D, et al. Veterinary compounding: the impact of different gelling agents on the rheological characteristics and release kinetics from meloxicam oral gels in the treatment of cats. *Vet Arhiv*. 2023;93(6):695–708.
doi:10.24099/vet.arhiv.2279.

13. Kočović D, **Mugoša S**, Shova S, Tomić Z, Jaćimović Ž. Crystal structure of 3-(4-bromophenyl)-5-methyl-1H-pyrazole, C₁₀H₉BrN₂. *Z Kristallogr New Cryst Struct*. 2023;238(5):863–865.
doi:10.1515/ncrs-2023-0242.
14. Adamov I, Stanojević G, Kočović D, **Mugoša S**, Grujić B, Ibrić S. Selective laser sintering (SLS) 3D printing process: influence of model design on the properties of zolpidem tartrate tablets. *Maced Pharm Bull*. 2023;69(Suppl 1):133–134.
doi:10.33320/maced.pharm.bull.2023.69.03.065.
15. Kočović D, **Mugoša S**. Falsifikovani lijekovi i farmaceutski kriminal. *Crnogorska revija za bezbjednost*. 2023;(2):71–84.
16. Šahman-Zaimović M, **Mugoša S**. Comparative analysis of the use of non-steroidal anti-inflammatory drugs in Montenegro, Finland and Croatia in the period 2010–2019. *Eur Rev Med Pharmacol Sci*. 2022;26(13):4789–4797.
doi:10.26355/eurrev_202207_29204.
17. **Mugosa S**, Radosavljevic I, Sahman M, Djordjevic N, Todorovic Z. Risk factors for adverse drug reactions associated with clopidogrel therapy. *Open Med (Wars)*. 2022;17(1):694–701.
doi: 10.1515/med-2021-0371
18. Antunović M, Lopičić M, Vučković L, Raonić J, **Mugoša S**. Prevalence and clinical implications of the HPV16 infection in oral cancer in Montenegro: evidence to support the immunization program. *Acta Microbiol Immunol Hung*. 2022;69(3):241–246.
doi:10.1556/030.2022.01794.
19. **Mugoša S**, Glušica A. Clinical trial challenges: impact of the new clinical trial regulation on the conduct of clinical trials. *Vojnosanit Pregl*. 2022;79(9):918–923.
doi:10.2298/VSP200316061M.
20. Mladenović K, Dragojević-Simić V, **Mugoša S**, Rancić N. Costs and consumption of analgesics, with special reference to opiates in Serbia and Montenegro from 2015 to 2019. *Vojnosanit Pregl*. 2022;79(12):1239–1247.
doi:10.2298/VSP210606002M.
21. **Mugoša S**, Kovačević A, Tomanić D, Kovačević Z. Trends of veterinary antibiotic use in Montenegro. In: Ružić Z, Galić I, editors. *Antimicrobial Resistance in Veterinary Medicine – Current State and Perspectives. Proceedings of the Conference, 21–23 June 2022, Novi Sad. University of Novi Sad, Faculty of Agriculture*; 2022:63–67.
22. Sahman M, **Mugosa S**, Rancic N. Utilization of mycophenolic acid, azathioprine, tacrolimus, cyclosporin, sirolimus, and everolimus: multinational study. *Front Public Health*. 2021;9:671316.
doi: 10.3389/fpubh.2021.671316
23. Janković SM, Bogavac-Stanojević N, Mikulić I, Izetbegović S, Ilićević I, **Mugosa S**, et al. A questionnaire for rating health-related quality of life. *Zdr Varst*. 2021;60(4):260–268.
doi:10.2478/sjph-2021-0035.
24. **Mugoša S**, Todorović Z, Cukić J, Šahman-Zaimović M, Đorđević N. ABCB1 polymorphism in clopidogrel-treated Montenegrin patients. *Open Life Sci* 2021;16(1):142–149.
<https://doi.org/10.1515/biol-2021-0017>
25. **Mugoša S**, Džamić Z, Šahman – Zaimović M, Lukovac-Janjić N. Adverse drug reactions associated with sunitinib therapy: characteristics and risk factors. *Vojnosanit Pregl* 2021; 77(4): 456–461.
<https://doi.org/10.2298/VSP201109145M>
26. **Mugoša S**, Stanković M, Turković N, Šahman – Zaimović M, Bešović Ž, Drljević M. Pharmacovigilance as an imperative of modern medicine. *Vojnosanit Pregl* 2017; 74(2): 167–172.
<https://doi.org/10.2298/VSP150428167M>

27. **Mugoša S**, Đorđević N, Đukanović N, Protić D, Bukumirić Z, Radosavljević I, Bošković A, Todorović Z. Factors affecting the development of adverse drug reactions to β -blockers in hospitalized cardiac patient population. *Patient Preference Adherence* 2016; 10:1461-9.
<https://doi.org/10.2147/PPA.S108579>
28. **Mugoša S**, Đorđević N, Bukumirić Z, Đukanović N, Cukić J, Radosavljević I, Baskić D, Protić D, Zdravković M, Todorović Z. PREDICT score and CYP2C19 polymorphism independently predict lack of efficacy of clopidogrel in cardiology patients. *Clin Exp Pharmacol Physiol* 2016; 43(3): 379-81.
<https://doi.org/10.1111/1440-1681.12531>
29. Šoškić M, Dabanović V, Čukić A, **Mugoša S**. Benzodiazepine use among the general population in the municipality of Berane, Montenegro. *Rational therapy* 2016; 8(2): 9-14.
<https://doi.org/10.5937/racter8-10932>
30. **Mugoša S**. Farmakogenetika – budućnost farmakoterapije. *Bilten Farmaceutске komore Crne Gore* 2016; 5:29-31.
31. **Mugoša S**, Bukumirić Z, Kovačević A, Bošković A, Protić D, Todorović Z. Adverse drug reactions in hospitalised cardiac patients: characteristics and risk factors. *Vojnosanit Pregl* 2015; 72(11): 975–981.
<https://doi.org/10.2298/VSP140710104M>
32. **Mugoša S**, Kučević B, Rolevski M, Bukumirić Z, Bešović Ž, Drljević M. Public Awareness and Perception of Clinical Trials in Montenegro. *Hospital Pharmacology*. 2015; 2(3): 317-321.
<https://doi.org/10.5937/hpimj1503317M>
33. **Mugoša S**, Stanković M, Turković N, Šahman – Zaimović M. Medical Dictionary MedDRA - used in over 60 countries, among which is Montenegro. *Hospital Pharmacology* 2015; 2(2): 266-271.
<https://doi.org/10.5937/hpimj1502266M>
34. **Mugoša S**, Stanković M, Turković N, Šahman – Zaimović M, Bešović Ž, Drljević M. Pharmacovigilance: empowering healthcare professionals. *Hospital Pharmacology* 2015; 2(2): 255-260.
<https://doi.org/10.5937/hpimj1502255M>
35. Protić D, Baltić S, Vujašinovic Stupar N, Pavlov-Dolijanović S, **Mugoša S**, Todorović Z. A case of myositis with immunological background associated with statin use. *Cent Eur J Med* 2014; 9(5): 619-24.
<https://doi.org/10.2478/s11536-013-0313-z>
36. **Mugoša S**, Todorović Z, Bošković A. Frequency of adverse drug reactions in hospitalized patients in Cardiology center of Clinical centre of Montenegro. *Pharmaca Serbica* 2011, 3(1-2): 7-11.
37. **Mugoša S**, Duborija-Kovačević N. Bolnička upotreba lijekova na četiri hirurške klinike Kliničkog centra Crne Gore. *Med zap* 2006 (61): 121-31.

Abstracts of Presentations at Scientific Meetings

38. **Mugoša S**, Babović T, Boljević G-Stanojević, Mićović T, Novaković N. New regulations in Montenegro – new rules in the fight against antimicrobial resistance. In: 5th International Conference Antimicrobial Resistance – Current State and Perspectives: From Science to Practice. Book of Abstracts, 28–30 May 2026, Novi Sad. University of Novi Sad, Faculty of Agriculture; 2026:24.
39. **Mugoša S**, Čizmović L, Tomanić D, Kovačević Z. Antimicrobial consumption in Montenegro from 2009 to 2024. In: 4th International Conference Antimicrobial Resistance – Current State and Perspectives. Book of Abstracts, 19–21 June 2025, Novi Sad. University of Novi Sad, Faculty of Agriculture; 2025:6.
40. Vukicevic V, Vujovic S, Cizmovic L, Stanojevic G, **Mugosa S**, Vezmar Kovacevic S. The awareness, knowledge and behaviour regarding valproate pregnancy prevention programme – questionnaire survey among patients in Montenegro [abstract]. In: 24th ISoP Annual Meeting “Pharmacovigilance: Back to the Future”; 2025 Oct 24–27; Cairo, Egypt. Drug Saf. 2025;48:1433–1660.
41. Vukicevic V, **Mugosa S**, Boljevic Stanojevic S, Vezmar Kovacevic S. Effects of the regulatory measures on valproate prescription in Montenegro – a seven-year national retrospective study [abstract]. In: 24th ISoP Annual Meeting “Pharmacovigilance: Back to the Future”; 2025 Oct 24–27; Cairo, Egypt. Drug Saf. 2025;48:1433–1660.
42. **Mugoša S**, Čizmović L, Tomanić D, Kovačević Z. Antimicrobial consumption in Montenegro from 2009 to 2022. In: 3rd International Conference Antimicrobial Resistance – Current State and Perspectives. Book of Abstracts, 16–18 May 2024, Novi Sad. University of Novi Sad, Faculty of Agriculture; 2024:25.
43. Vukicevic V, **Mugosa S**, Vezmar Kovacevic S. Are men and women equal when it comes to valproates – analysis of prescribing practice in Montenegro [abstract]. In: 23rd ISoP Annual Meeting “Global Perspectives on Pharmacovigilance in the Digital Age and Advanced Therapeutics”; 2024 Oct 1–5; Montreal, Canada. Drug Saf. 2024;47:1307–1439.
44. **Mugoša S**, Babović T, Boljević G, Tomanić D, Tešin N. Critically important antimicrobial from human practice trend of use in veterinary medicine in Montenegro. In: 2nd International Conference Antimicrobial Resistance in Veterinary Medicine – Current State and Perspectives. Book of Abstracts, 22–24 June 2023, Novi Sad. University of Novi Sad, Faculty of Agriculture; 2023:56–57.
45. **Mugosa S**. Pharmacogenetic factors affecting adverse drug reactions of β -blockers [abstract]. In: 22nd ISoP Annual Meeting “Putting Patients First in Pharmacovigilance: International Perspectives from Global South”; 2023 Nov 6–9; Bali, Indonesia. Drug Saf. 2023;46:1173–1295.
46. **Mugoša S**. Clinical trials challenges – Good Clinical Practice Guidelines (abstract). Montenegrin international medical summit, 3-6. oktobar 2019, Podgorica, Crna Gora. Abstrakt objavljen u: Abstract book 2019, p.44.
47. **Mugoša S**, Bešović Ž, Šahman-Zaimović M, Drljević M. Uticaj nove Regulative Evropske unije na sprovođenje kliničkih ispitivanja u regionu (The impact of new European Union Regulation on conducting clinical trials in the region) (abstract). 14. Kongres farmakologa i 4. Kongres kliničke farmakologije Srbije sa međunarodnim učešćem, 18-21. septembar 2019, Novi Sad, Srbija. Abstrakt objavljen u: Abstract book 2019, p.128-129.
48. **Mugoša S**, Todorović Z, Đorđević N. Impact of genetic and non-genetic factors on clopidogrel efficacy (abstract). International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2018: New Perspectives for Improving 21st Century Health Systems, 10-14. novembar 2018, Barselona, Španija. Abstrakt objavljen u časopisu sa SCI liste: Value in Health 2018 Oct 01; 21(Suppl 3):S96.
49. Kucevic B, Rolevski M, Sahman-Zaimovic M, Besovic Z, **Mugosa S**. Promoting public awareness of clinical trials in Montenegro (abstract). 12th Congress of the European Association for Clinical Pharmacology and Therapeutics, 27-30. jun 2015, Madrid, Španija. Abstrakt objavljen u časopisu sa SCI liste: Clinical Therapeutics 2015 Aug; 37(8S): e.39.
50. Turković N, Stanković M, Bešović Ž, Čizmović L, **Mugoša S**. Važna uloga farmaceuta u prijavljivanju neželjenih dejstava lijekova (abstract). II Kongres farmaceuta Crne Gore sa međunarodnim učešćem, 28-31. maj 2015, Budva, Crna Gora. Abstrakt objavljen u: Zbornik sažetaka 2015, p.188.

51. Šarkinović E, Bešović Ž, Drljević M, Šahman-Zaimović M, **Mugoša S**. Regulatorni osvrt na biološki slične lijekove (abstract). II Kongres farmaceuta Crne Gore sa međunarodnim učešćem, 28-31. maj 2015, Budva, Crna Gora. Abstrakt objavljen u: Zbornik sažetaka 2015, p.179.
52. Stanković M, Turković N, Čizmović L, Bešović Ž, **Mugoša S**. Promjene u potrošnji diklofenaka kao rezultat komunikacije prema zdravstvenim radnicima (abstract). II Kongres farmaceuta Crne Gore sa međunarodnim učešćem, 28-31. maj 2015, Budva, Crna Gora. Abstrakt objavljen u: Zbornik sažetaka 2015, p.177-178.
53. **Mugoša S**, Todorović Z, Šahman-Zaimović M, Drljević M, Đorđević N. Polimorfizam CYP2D6 – faktor rizika za nastanak neželjenih dejstava beta blokatora (abstract). II Kongres farmaceuta Crne Gore sa međunarodnim učešćem, 28-31. maj 2015, Budva, Crna Gora. Abstrakt objavljen u: Zbornik sažetaka 2015, p.156-157.
54. Kučević B, Rolevski M, Šahman-Zaimović M, Bešović Ž, **Mugoša S**. Stavovi i informisanost opšte javnosti o kliničkim ispitivanjima (abstract). II Kongres farmaceuta Crne Gore sa međunarodnim učešćem, 28-31. maj 2015, Budva, Crna Gora. Abstrakt objavljen u: Zbornik sažetaka 2015, p.139-140.
55. Mikov M, Goločorbin-Kon S, **Mugoša S**. Značaj pretkliničke i kliničke farmakovigilance za farmakoterapiju (abstract). II Kongres farmaceuta Crne Gore sa međunarodnim učešćem, 28-31. maj 2015, Budva, Crna Gora. Abstrakt objavljen u: Zbornik sažetaka 2015, p.60.
56. **Mugosa S**, Bukumiric Z, Protic D, Todorovic Z. Influence of pharmacological education on awareness of the risk of adverse drug reactions (abstract). 11th Conference of the European Association for Clinical Pharmacology and Therapeutics, 28-31. avgust 2013, Ženeva, Švajcarska. Abstrakt objavljen u časopisu sa SCI liste: Clinical Therapeutics 2013 Aug; 35(8S): e.26.
57. **Mugoša S**, Todorović Z, Šahman-Zaimović M. Adverse drug reactions and polypharmacy in cardiac patients (abstract). 18th Scientific Symposium of the Austrian Pharmacological Society (APHAR), 20-21. septembar 2012, Grac, Austrija. Abstrakt objavljen u časopisu sa SCI liste: BMC Pharmacology and Toxicology 2012 Sep 17; 13(Suppl 1):A39.